Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love")

Neuropharmacology

Volumn 50, Issue 1, 2006, Pages 69-80

  McNamara, Ruth ^a   Kerans, Aoife ^a   O'Neill, Barry ^a   Harkin, Andrew ^a,b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Caffeine; Hyperthermia; MDMA; Neurotoxicity; Rat; Serotonergic loss

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; AMPHETAMINE DERIVATIVE; CAFFEINE; SEROTONIN;

5 HYDROXYINDOLEACETIC ACID BRAIN LEVEL; ACUTE TOXICITY; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; HIPPOCAMPUS; HYPERTHERMIA; HYPOTHERMIA; LETHALITY; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; BODY TEMPERATURE; BRAIN CHEMISTRY; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG TOLERANCE; FEVER; HALLUCINOGENS; HYDROXYINDOLEACETIC ACID; MALE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; SEROTONIN;

EID: 30344471062     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2005.08.006     Document Type: Article

References (35)

1. A. Apter, H.M. van Praag, R. Plutchik, S. Sevy, M. Korn, and S.L. Brown Interrelationships among anxiety, aggression, impulsivity, and mood: a serotonergically linked cluster? Psychiatry Res. 32 1990 191 199
2. G. Battaglia, J. Sharkey, M.J. Kuhar, and E.B. de Souza Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography Synapse 8 1991 249 260
3. C. Burgess, A. O'Donohoe, and M. Gill Agony and ecstasy: a review of MDMA effects and toxicity Eur. Psychiatry 15 2000 287 294
4. J.C. Cole, and H.R. Sumnall Altered states: the clinical effects of ecstasy Pharmacol. Ther. 98 2003 35 58
5. R.W. Derlet, J.C. Tseng, and T.E. Albertson Potentiation of cocaine and d-amphetamine toxicity with caffeine Am. J. Emerg. Med. 10 1992 211 216
6. B.B. Fredholm, K. Battig, J. Holmen, A. Nehlig, and E.E. Zvartau Actions of caffeine in the brain with special reference to factors that contribute to its widespread use Pharmacol. Rev. 51 1999 83 133
7. R. Garcia-Repetto, E. Moreno, T. Soriano, C. Jurado, M.P. Gimenez, and M. Menendez Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose Forensic Sci. Int. 135 2003 110 114
8. A.R. Green, A.O. Mechan, J.M. Elliott, E. O'Shea, and M.I. Colado The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") Pharmacol. Rev. 55 2003 463 508
9. A.R. Green, E. O'Shea, and M.I. Colado A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response Eur. J. Pharmacol. 500 2004 3 13
10. C.G. Gurtman, K.C. Morley, K.M. Li, G.E. Hunt, and I.S. McGregor Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion Eur. J. Pharmacol. 446 2002 89 96
11. H.F. Hardman, C.O. Haavik, and M.H. Seevers Relationship of the structure of mescaline and seven analogs to toxicity and behaviour in five species of laboratory animals Toxicol. Appl. Pharmacol. 25 1973 299 309
12. A. Harkin, T.J. Connor, J. Mulrooney, J.P. Kelly, and B.E. Leonard Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats Life Sci. 68 2001 1367 1382
13. A. Harkin, J.M. O'Donnell, and J.P. Kelly A study of VitalView for behavioural and physiological monitoring in laboratory rats Physiol. Behav. 77 2002 65 77
14. A. Harkin, E. Shanahan, J.P. Kelly, and T.J. Connor Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine Eur. J. Neurosci. 18 2003 1021 1027
15. K.M. Hegadoren, G.B. Baker, and M. Bourin 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans Neurosci. Biobehav. Rev. 23 1999 539 553
16. J.A. Henry, K.J. Jeffreys, and S. Dawling Toxicity and deaths from 3, 4 methylenedioxymethamphetmaine, ("Ecstasy") Lancet 340 1992 384 387
17. 3H]dopamine release from superfused rat brain slices Eur. J. Pharmacol. 132 1986 269 276
18. U.D. McCann, and G.A. Ricaurte Lasting neuropsychiatric sequelae of (+/-) methylenedioxymethamphetamine ('ecstasy') in recreational users J. Clin. Psychopharmacol. 11 1991 302 305
19. U.D. McCann, A. Ridenour, Y. Shaham, and G.A. Ricaurte Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans Neuropsychopharmacology 10 1994 129 138
20. U.D. McCann, V. Eligulashvili, and G.A. Ricaurte Adverse neuropsychiatric events associated with dexfenfluramine and fenfluramine Prog. Neuropsychopharmacol. Biol. Psychiatry 22 1998 1087 1102
21. U.D. McCann, V. Eligulashvili, and G.A. Ricaurte (+/-)3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies Neuropsychobiology 42 2000 11 16
22. U.D. McCann, and G.A. Ricaurte Caveat emptor: editors beware Neuropsychopharmacology 24 2001 333 336
23. A.O. Mechan, B. Esteban, E. O'Shea, J.M. Elliott, M.I. Colado, and A.R. Green The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats Br. J. Pharmacol. 135 2002 170 180
24. T.J. Monks, F. Bai, R.T. Miller, and S.S. Lau Serotonergic neurotoxicity of methylenedioxyamphetamine and methylenedioxymetamphetamine Adv. Exp. Med. Biol. 500 2001 397 406
25. M.J. Morgan Ecstasy (MDMA): a review of its possible persistent psychological effects Psychopharmacology (Berl) 152 2000 230 248
26. K.C. Morley, J.E. Gallate, G.E. Hunt, P.E. Mallet, and I.S. McGregor Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy") Eur. J. Pharmacol. 433 2001 91 99
27. J.F. Nash, and D.E. Nichols Microdialysis studies on 3,4- methylenedioxyamphetamine and structurally related analogues Eur. J. Pharmacol. 200 1991 53 58
28. E.D. O'Loinsigh, G. Boland, J.P. Kelly, and K.M. O'Boyle Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat Prog. Neuropsychopharmacol. Biol. Psychiatry 25 2001 621 638
29. A.C. Parrott Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity Psychopharmacology (Berl) 173 2004 234 241
30. S. Ramcharam, P.L. Meenhorst, J.M.M.B. Otten, C.H.W. Koks, D. De Boer, R.A.A. Maes, and J.H. Beijem Survival after massive ecstasy overdose Clin. Toxicol. 36 1998 727 731
31. G.A. Ricaurte, L.E. DeLanney, S.G. Wiener, I. Irwin, and J.W. Langston 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates Brain Res. 474 1988 359 363
32. G.A. Ricaurte, J. Yuan, and U.D. McCann (+/-)3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals Neuropsychobiology 42 2000 5 10
33. G.A. Ricaurte, and U.D. McCann Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons Neurotox. Res. 3 2001 85 99
34. H. Series, S. Boeles, E. Dorkins, and R. Peveler Psychiatric complications of ecstasy use J. Psychopharmacol. 8 1994 60 61
35. L.J. Spanos, and B.K. Yamamoto Acute and subchronic effects of methylenedioxy methamphetamine [(+/-) MDMA] on locomotion and serotonin syndrome behavior in the rat Pharmacol. Biochem. Behav. 32 1989 835 840